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Abstract
The present study evaluated an internet-delivered pain management program, the Pain Course, when provided with different levels
of clinician support. Participants (n5 490) were randomised to 1 of 4 groups: (1) Regular Contact (n5 143), (2) Optional Contact (n5
141), (3) No Contact (n5 131), and (4) a treatment-as-usual Waitlist Control Group (n5 75). The treatment program was based on
the principles of cognitive behaviour therapy and comprised 5 internet-delivered lessons provided over 8 weeks. The 3 Treatment
Groups reported significant improvements (between-group Cohen’s d; avg. reduction) in disability (ds $ 0.50; avg. reduction $
18%), anxiety (ds$ 0.44; avg. reduction$ 32%), depression (ds$ 0.73; avg. reduction$ 36%), and average pain (ds$ 0.30; avg.
reduction $ 12%) immediately posttreatment, which were sustained at or further improved to 3-month follow-up. High treatment
completion rates and levels of satisfaction were reported, and no marked or consistent differences were observed between the
Treatment Groups. The mean clinician time per participant was 67.69 minutes (SD5 33.50), 12.85 minutes (SD5 24.61), and 5.44
minutes (SD5 12.38) for those receiving regular contact, the option of contact, and no clinical contact, respectively. These results
highlight the very significant public health potential of carefully designed and administered internet-delivered pain management
programs and indicate that these programs can be successfully administered with several levels of clinical support.
Keywords: Internet, Online, Pain management, Cognitive behaviour therapy, CBT, Pain, Chronic pain, Anxiety, Depression,
Disability, Randomised controlled trial
1. Introduction
There is now substantial support for pain management programs
for chronic pain.11,21,40 There is also a growing recognition that
many people are unable to access these programswhen they are
administered in their traditional face-to-face format.24,31 Barriers
to accessing face-to-face programs are numerous and include
costs, mobility limitations, stigma, availability, and long waiting
lists. Consequently, many people fail to receive or experience
considerable delays in accessing evidence-based care.31
One innovative approach with the potential to increase access
to pain management programs is delivery through the inter-
net.27,42 Internet-delivered programs use the same principles,
content, and components as face-to-face programs but can be
provided with varying levels of clinician support ranging from
regular clinician contact through e-mail or telephone to no
clinician support at all.1,2,13 To date, the majority of internet-
delivered programs for chronic pain have been based on
cognitive behaviour therapy (CBT) (eg, 7,8,10,12,15,41,56) but
some are emerging based on mindfulness and acceptance
therapies (eg, 9,18,23). Systematic reviews and a meta-analysis
have found evidence of small but clinically significant improve-
ments in the primary domains targeted in pain management
programs (eg, disability, anxiety, depression).3,19,32 However, as
with face-to-face programs,11,20,21,40 clinical improvements have
not been consistently observed in all studies and the magnitude
of improvements has varied considerably across studies.3,15,19,32
One explanation for the inconsistent outcomes of internet-
delivered programs for chronic pain has been the absence of
regular clinician support in most studies.15 Highlighting this, one
of the only studies (n 5 62) to examine a CBT program involving
regular clinical support (ie, average 81 minutes per participant),
the Pain Course, found very high completion and satisfaction
rates as well as moderate-to-large improvements across the
primary domains of anxiety, depression, and disability.15 How-
ever, challenging the importance of clinical support, several
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studies in the broader mental health literature have started to
report good clinical outcomes without clinician support
(eg,4,5,50,51). This has led a recent review to suggest that
clinician support may be less important where internet-delivered
programs are sufficiently credible, engaging, of a high quality and
involve some level of screening for suitability.2 Unfortunately, no
studies have directly examined these issues or the importance of
clinician support in the context of internet-delivered pain
management programs.
The present study sought to replicate the results of the initial
trial of the Pain Course and examine its efficacy when provided
with different levels of clinical support. After a brief screening
interview, participants were randomised to 1 of 4 groups: (1)
Regular Contact Group, (2) Optional Contact Group, (3) No
Contact Group, and (4) a treatment-as-usual Waitlist Control
Group. It was hypothesised that participants in the 3 Treatment
Groups would report significant improvements on clinical
measures of disability, anxiety, depression, and pain relative to
the Control Group, and that the Regular Contact Group would
report greater improvements compared with the Optional
Contact and No Contact Groups. It was hypothesised that
outcomeswould bemaintained at 3-month follow-up and that the
intervention would be found to be acceptable.
2. Methods
2.1. Participants
Participants read about the study and applied to participate
through thewebsite of the eCentreClinic (www.ecentreclinic.org).
The eCentreClinic is a specialist research unit that provides
information about common mental and chronic health conditions
and offers the opportunity for free psychological treatment
through participation in clinical trials. Because of the information
offered and the potential to receive free treatment, the
eCentreClinic can be located through online searches and is
promoted by various health professionals and through numerous
websites within Australia. The present trial was also promoted
using paid advertisements placed in state newspapers and using
unpaid general advertisements by a range of governmental and
nongovernmental organisations providing services to adults with
chronic pain, including Chronic Pain Australia, the Australian Pain
Management Association, the NSW Agency for Clinical In-
novation, Pain Network, Pain Australia, and Arthritis Australia.
No monetary rewards were provided for participation or for
completion of questionnaires.
Six hundred and fourteen people with a broad range of chronic
pain conditions submitted applications to participate in the course,
which involved completing several online questionnaires and a brief
telephone assessment to ensure participants satisfied the inclusion
and exclusion criteria. All applications were randomly allocated to 1
of 4 groups using a permuted block randomisation sequence (ie,
with 14 randomisations per block) and a 2:2:2:1 allocation ratio with
the Waitlist Control Group designed to have half the participants of
the Treatment Groups. The randomisation sequence was created
by B. F. Dear. using an online randomiser (www.random.org), and
participant randomisation occurred at the point of application,
through the eCentreClinic software system, before participants had
any contact with the researchers or the researchers had the
opportunity to review the details of participants’ applications. Thus,
the researchers were blind to group allocation until the participant
was deemed to have made a successful or unsuccessful
application. The researchers sought to recruit at least 350
participants, which, with alpha set at 0.05 and a power of 0.80,
would enable the detection of small effect sizes differences (ie,
Cohen’s ds. 0.35) between the TreatmentGroups andmoderate-
to-large effect size differences (ie, Cohen’s ds. 0.50) between the
Treatment Groups and Control Group. However, more participants
were recruited to compensate for both withdrawals and question-
naire nonresponse at posttreatment and follow-up. Of the 614
people who started an application, 490 met the following inclusion
criteria: (1) experienced pain for more than 6 months, (2) had their
pain assessed by their general practitioner or a specialist within the
last 3months, (3) were at least 18 years of age, (4) were a resident of
Australia, (5) had regular access to a computer and the internet, and
(6) were not currently experiencing an unmanaged psychotic illness
or very severe symptoms of depression (ie, defined as a total score
.22 or endorsing a score .2 to item 9 of the Patient Health
Questionnaire 9-item [PHQ-9]29). The CONSORT flowchart for the
trial is displayed in Figure 1.
The 490 participants who met all the inclusion criteria were
informed through e-mail of their randomisation to 1 of 4 groups: (1)
Regular Contact Group (n5 143), (2) Optional Contact Group (n5
141), (3) No Contact Group (n 5 131), or (4) treatment-as-usual
Waitlist Control Group (n 5 75). Participants’ primary general
practitioner or medical specialist was sent a letter notifying them of
the patient’s participation, describing the nature of the study and
program, and inviting direct contact. The study was approved by
the Human Research Ethics Committee of Macquarie University,
Sydney, Australia, and the trial was registered on the
Australian and New Zealand Clinical Trials Registry (ANCZTR)
as ACTRN12613000252718. Participant demographic and
pain-related characteristics are shown in Tables 1 and 2.
2.2. Design and measures
The study used a 4-arm CONSORT-revised compliant rando-
mised controlled trial comparing an internet-delivered treatment
for managing chronic pain, the Pain Course, provided with 3
different levels of clinical support: (1) Regular Contact Group, (2)
Optional Contact Group and (3) No Contact Group with (4)
a treatment-as-usual Waitlist Control Group. After treatment of
the 3 Treatment Groups, participants in theWaitlist Control Group
were provided access to the course; the majority of whom also
volunteered to participate in a separate trial involving an
enhanced version of the course (ACTRN12612000556842) and
the results of which are not reported in this article. All outcome
measures were administered online. The primary and secondary
measures were administered at initial assessment, pretreatment,
posttreatment and 3-month follow-up. Pain was considered
a secondary outcome because the program focuses on the
management of pain-related disability and emotional wellbeing.
The tertiary measures were administered at pretreatment,
posttreatment and 3-month follow-up and the acceptability and
satisfaction questions were administered at posttreatment. The
tertiary measures were administered to assess psychological
variables, which have been identified in previous literature as
important psychological targets of face-to-face pain manage-
ment programs and as important factors in biopsychosocial
models of chronic pain. However, a comprehensive examination
of these variables is outside the scope of the current trial and will
be reported in subsequent studies.
All 4 groups completed questionnaires at initial assessment,
pretreatment, and posttreatment, but only the 3 Treatment
Groups completed questionnaires at 3-month follow-up, as the
Waitlist Control Group had entered active treatment. The
pretreatment measures were administered immediately before
the start of the Course, and the posttreatment measures were
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completed after the completion of the 8-week Course. As
a clinical trial of a psychological treatment with a treatment-as-
usual Waitlist Control Group, it was not possible to blind
participants or clinicians to group allocation.
2.2.1. Primary measures
2.2.1.1. Roland–Morris Disability Questionnaire
The Roland–Morris Disability Questionnaire (RMDQ) is a 24-
statement checklist designed to measure disability associated
with chronic pain.43 The RMDQ asks participants to endorse their
ability to do numerous day-to-day physical activities. Higher
scores are associatedwith greater disability. Amodified version of
the RMDQ, which is applicable to a broader range of chronic pain
conditions (ie, references to “my back pain” changed to “my
pain”),35 was used in the present study. This version of the RMDQ
is widely used in Australia, and considerable normative data are
therefore available for benchmarking purposes (eg, 35). The
RMDQ has yielded good psychometric properties with high levels
of internal consistency and test–retest reliability.44 In the present
sample, Cronbach’s a 5 0.86.
2.2.1.2. Patient Health Questionnaire 9-item
The PHQ-9 contains 9 items that measure the symptoms and
severity of depression according to DSM-IV criteria.29 Higher
scores indicate greater depression symptom severity, and a total
score of$10 is indicative of a DSM-IV diagnosis of depression.29
The PHQ-9 has been found to have good psychometric
properties29 and to be sensitive to treatment-related change.54
In the present study, Cronbach’s a 5 0.84.
2.2.1.3. Generalized Anxiety Disorder 7-item Scale
The Generalized Anxiety Disorder 7-item (GAD-7) Scale contains 7
items designed to measure symptoms of anxiety and is sensitive to
DSM-IV congruent generalised anxiety disorder, panic disorder, and
social anxiety disorder, with higher scores indicating greater severity
Figure 1. Participant flow from application to 3-month follow-up. Tx, treatment; 3M FU, 3-month follow-up; NR, Non-response.
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of anxiety symptoms.30,45 The GAD-7 has been found to have good
psychometric properties30 and to be sensitive to treatment-related
change.16 In the current sample, Cronbach’s a 5 0.89.
2.2.2. Secondary measure
2.2.2.1. Wisconsin Brief Pain Questionnaire
The Wisconsin Brief Pain Questionnaire (WBPQ) is designed to
assess the location, severity, and duration of a person’s pain as
well as the level of interference associated with pain.14 Only the 4
WBPQ items concerning the intensity of participants’ current
pain, average pain, least pain and worst pain over the last month
were used in the present study. These items ask for ratings of pain
on a 10-point scale where 0 reflects no pain and 10 indicates the
worst pain imaginable.
2.2.3. Tertiary measures
2.2.3.1. Pain Self-Efficacy Questionnaire
The Pain Self-efficacy Questionnaire (PSEQ) contains 10 state-
ments regarding a patient’s beliefs about his or her ability to
undertake a number of daily tasks with pain.34 Higher scores
indicate greater pain-related self-efficacy. The PSEQ has been
found to possess good internal consistency and test–retest
reliability.34 In the present sample, Cronbach’s a 5 0.91.
2.2.3.2. Tampa Scale of Kinesiophobia
The Tampa Scale of Kinesiophobia (TSK) contains 17 statements
and is designed to measure fears of movement and reinjury.28
Higher scores indicate higher fears ofmovement and reinjury. The
TSK has been found to predict behavioural performance on
movement tasks55 and has been found to possess good levels of
internal consistency and reliability.48 In the present sample,
Cronbach’s a 5 0.80.
2.2.3.3. Chronic Pain Acceptance Questionnaire 8-item
The Chronic Pain Acceptance Questionnaire 8-item (CPAQ-8)
contains 8 items designed to measure acceptance in the context
of chronic pain.22 It comprises 2 subscales, which measure
engagement in meaningful activities in the presence of chronic
pain (ie, the Activity Engagement Subscale) and willingness to
experience pain without trying to control or avoid pain (ie, the Pain
Willingness Subscale). Higher scores indicate greater willingness
to experience and acceptance of pain. These 2 subscales can be
examined separately or in combination, and the CPAQ-8 has
been found to possess good psychometric properties.22 In the
present sample, Cronbach’s a 5 0.79.
2.2.3.4. Prescription medication and health care service use
Medication and health care service use data were collected using
a previously used and purpose-built questionnaire17,53 based on
the TiC-P.6 This questionnaire asks participants about their (1)
primary and secondary health care consultations and admissions,
Table 1









n % n % n % n % n %
Gender
Male 27 19 24 18 25 20 20 27 96 20 x2 5 2.65, P 5 0.448
Female 112 81 111 82 98 80 54 73 375 80
Age (years)
Mean 50 (13) 49 (12) 50 (14) 52 (13) 50 (13) F 5 1.13, P 5 0.336
Range 22-86 22-79 20-85 19-74 19-86
18-29 10 7 12 9 9 7 6 8 37 8 x2 5 7.75, P 5 0.559
30-55 77 55 86 64 70 57 39 53 272 58
56-64 30 22 23 17 23 19 12 16 88 19
651 22 16 14 10 21 17 17 23 74 16
Marital status
Single/never married 25 18 31 23 27 22 17 23 100 21 x2 5 13.36, P 5 0.147
Married/de facto 93 67 80 59 70 57 38 51 281 60
Separated/divorced/widowed 20 14 16 12 22 18 17 23 75 16
Education
High school or less 38 27 33 24 26 21 22 30 119 25 x2 5 2.70, P 5 0.845
Certificate/diploma/other 36 26 39 29 39 32 20 27 134 28
University 65 47 63 47 58 47 32 43 218 46
Employment/vocational status*
Full-time employment 39 28 29 22 28 23 13 18 109 23 x2 5 3.40, P 5 0.334
Part-time employment 18 13 28 21 19 15 14 19 79 17 x2 5 3.37, P 5 0.337
Casual employment 15 11 16 12 12 10 7 10 50 11 x2 5 0.42, P 5 0.936
Full-time student 3 2 4 3 3 2 2 3 12 3 —
Part-time student 9 7 8 6 10 8 4 5 31 7 —
Unemployed 16 12 25 19 15 12 8 11 64 14 x2 5 3.99, P 5 0.262
Seeking employment 9 7 5 4 4 3 3 4 21 5 —
Registered disability 27 19 29 22 27 22 20 27 103 22 x2 5 1.65, P 5 0.648
Retired 30 22 20 15 22 18 15 20 87 19 x2 5 2.27, P 5 0.517
SDs are shown in parentheses. All data were self-reported. Numbers and percentages are rounded to the nearest whole number. Chi-square statistics are not reported where cells have an n # 5.
* Categories of employment and vocational status were not mutually exclusive; participants could indicate more than one to best describe their situation.
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and (2) the use of prescription pain, pain-related, antidepres-
sant, and anxiolytic medications. To collect data about health
service use, participants were presentedwith a range of relevant
health professionals and services (ie, general practitioner,
nurse, medical specialist, psychologist, counsellor, physiother-
apist, telephone crisis service, and hospital emergency de-
partment) and asked to indicate how many times they had seen
those health professionals or used those services in the previous
8 weeks due to pain, anxiety, or depression. To collect data
about medication use, participants were asked to indicate the
names of up to 5 medications they had been prescribed and
were using for pain, pain-related conditions, anxiety, or
depression and how long they had been using the medications.
These medications were categorised by the researchers based
on the class of medications to which they belong (Table 6) and
opioid medications were categorised based on their oral
morphine equivalent with medications with a conversion factor
$1 being considered strong and #1 being considered weak.38
2.2.4. Acceptability and satisfaction
Treatment satisfaction and acceptability were assessed at
posttreatment using 3 questions: (1) “Overall, how satisfied were
you with the Course?” (2) “Would you feel confident in
recommending this Course?” and (3) “Was it worth your time
doing the Course?” Participants responded to the first question
Table 2











n % n % n % n % n %
Previously attended specialist pain clinic 68 48 76 56 72 58 35 47 251 53 x2 5 1.72, P 5 0.632
Compensation claim regarding pain 36 25 33 24 37 30 25 33 131 28 x2 5 2.64, P 5 0.450
Mean pain duration (years) 9.34 (8.33) 8.66 (6.78) 9.58 (9.05) 10.23
(10.83)
9.35 (8.22) F 5 0.62, P 5 0.596
Average pain (last month) 5.71 (1.62) 5.70 (1.47) 5.90 (1.54) 6.01 (1.51) 5.80 (1.54) F 5 1.00, P 5 0.392
Average number of pain sites 3.32 (1.29) 3.41 (1.21) 3.25 (1.23) 3.24 (1.18) 3.32 (1.23) F 5 0.44, P 5 0.724
Pain-free period (last month) 6 4 11 8 10 8 3 4 30 6 x2 5 3.00, P 5 0.391
Pain location
Head/face/mouth 54 38 54 40 45 36 25 33 178 38 x2 5 0.92, P 5 0.819
Neck/shoulders/upper back 108 77 106 78 94 76 56 75 364 77 x2 5 0.29, P 5 0.962
Arms/forearms/hands 79 56 80 59 65 52 40 54 264 56 x2 5 1.23, P 5 0.745
Lower back/pelvis/sacrum 114 82 117 86 108 87 60 81 399 85 x2 5 2.84, P 5 0.417
Legs/knees/feet 107 77 103 76 87 70 57 77 354 75 x2 5 1.77, P 5 0.622
Prescription medications
Pain 107 76 98 72 93 75 55 74 353 75 x2 5 0.74, P 5 0.862
Mental health 66 47 57 42 54 43 31 41 208 44 x2 5 0.98, P 5 0.805
Prescription medications reported*
Strong opioid analgesics 49 35 47 35 43 35 48 65 187 40 x2 5 7.88, P 5 0.049
Weak opioid analgesics 43 31 51 38 43 35 28 38 165 35 x2 5 1.41, P 5 0.702
Nonsteroidal anti-inflammatories 29 21 31 23 29 24 18 24 107 23 x2 5 0.59, P 5 0.897
Disease-modifying antirheumatics 9 6 6 4 11 9 4 5 30 6 —
Anticonvulsants 40 29 33 24 37 30 31 42 141 30 x2 5 3.79, P 5 0.285
Benzodiazepines 22 16 24 18 17 14 21 28 84 18 x2 5 5.93, P 5 0.115
Anxiolytics and antidepressants 88 63 90 67 65 53 42 57 285 61 x2 5 1.29, P 5 0.731
Other pain or psychotropic medications 19 14 23 17 21 17 13 18 76 16 x2 5 1.86, P 5 0.603
Number of prescription medications*
0 28 20 23 17 17 14 6 8 74 16 x2 5 15.90, P 5 0.388
1 29 21 29 22 32 26 12 16 102 22
2 27 19 26 19 23 19 18 24 94 20
3 23 17 24 18 26 21 12 16 85 18
4 17 12 17 12 16 13 11 14 61 13
$5 15 10 16 11 9 7 15 20 55 11
Mean number of prescription medications* 2.15 (1.69) 2.26 (1.68) 2.16 (1.50) 2.77 (1.64) 2.28 (1.64)
Self-reported causes/diagnoses for pain†
Accident/injury 69 50 62 46 75 61 42 57 248 53 x2 5 6.87, P 5 0.076
Postmedical treatment 6 4 8 6 7 6 2 3 23 5 —
Complex regional pain syndrome 11 8 5 4 5 4 4 5 25 5 —
Fibromyalgia 28 20 39 29 17 14 11 15 95 20 x2 5 10.74, P 5 0.013
Neuropathic/neurological conditions‡ 9 6 7 5 5 4 5 7 26 6 —
Rheumatic/autoimmune conditions§ 9 6 8 6 5 4 2 3 24 5 —
Osteoarthritis 29 21 25 19 19 15 18 24 91 19 x2 5 2.64, P 5 0.450
Spinal cord injury 0 0 1 1 3 2 2 3 6 1 —
SDs are shown in parentheses. All data were self-reported. Chi-square statistics are not reported where cells have an n # 5.
* Only prescription medications for pain, a pain-related condition, anxiety, or depression are reported. Strong opioids: buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone; weak opioids: codeine,
tramadol, tapentadol; anxiolytics and antidepressants: beta blockers, selective serotonin reuptake inhibitors, norepinephrine and serotonin–norepinephrine reuptake inhibitors, tricyclics and tetracyclics; other psychotropic or
pain medications including corticosteroids, antispasmodics, serotonin agonists, dopamine agonists, antipsychotics, and psychostimulants.
† Self-reported causes or diagnoses related to pain: causes and diagnoses not mutually exclusive, and many others were reported.
‡ Conditions counted were peripheral neuropathy, postherpetic neuralgia, trigeminal neuralgia, and multiple sclerosis.
§ Conditions counted were rheumatoid arthritis, ankylosing spondylitis, and systemic lupus erythematosus.
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using a 5-point Likert scale, which ranged from “Very Satisfied” to
“Very Dissatisfied” and the latter 2 questions with a “Yes” or “No”
response. These questions have been used in previous research
examining the acceptability of other internet-delivered treatments
(eg, 17,26,49,53) and were used in the first trial of the Pain
Course.15 Several qualitative and free response questions were
also posed to the participants in order to guide future revisions
and improvements to the course.
2.3. Treatment program
The Pain Course is an efficacious internet-delivered pain
management program based on the principles of CBT15 and
has been developed alongside several other effective internet-
delivered treatment courses for other conditions (eg, 17,49–53). The
Pain Course is based on a pragmatic model of treatment that
aims to: (1) provide information that helps participants to
understand and deconstruct their symptoms and difficulties; (2)
teach a range of CBT skills to help participants manage their
symptoms and difficulties; and (3) reduce pain-related disability,
anxiety, and depression by encouraging the practice and
adoption of the skills taught within the program. Importantly,
the Pain Course was designed based on the principles of
transdiagnostic psychological intervention (eg, 52) and therefore
provides therapeutic information and teaches self-management
skills that are applicable to and effective for a broad range of pain
conditions and psychological difficulties. Consequently, there is
no tailoring of content or materials for individual participants; all
participants receive the same materials. An overview of the
structure, content, and skills taught within the Pain Course is
provided in Table 3.
The Pain Course consists of 5 core online lessons and 5 lesson
summaries, which provide homework assignments to assist
participants to learn and apply the skills described in the lessons.
Participants are strongly encouraged to practice the skills taught
within the course on a daily basis and to gradually adopt them into
their everyday lives. Additional resources are provided to
introduce additional topics and skills that are relevant for many
participants, but which are not described within the core lessons,
including materials on working with health professionals and
treatments for chronic pain, managing sleep, problem solving,
controlling attention and assertive communication. Comprehen-
sive case stories are provided, which describe how people with
chronic pain apply the information and skills covered in the
course. All course materials are accessed through a personal
password-protected login to the eCentreClinic software system,
which is provided to participants once they are accepted into the
Course. All materials are released systematically over 8 weeks
and participants are unable to access materials in later weeks
without first having read previous materials. However, once
available, participants could view and review materials as desired
andmaterials could be printed for offline use based on participant
preference. The eCentreClinic system tracks participants’ logins
and general use of the Pain Course, including the completion of
lessons and the viewing and download of the lesson summaries
and other additional resources. Participants were provided with
Table 3
Timetable and content of the Pain Course.
Lesson Time before next
lesson (weeks)
Lesson content Primary skill taught Additional resources
1 1 Education about the prevalence of chronic pain and
symptoms of anxiety and depression. Information
about pain perception and the nervous system.
Introduction of a CBT model and explanation of the
functional relationship between physical, thought,
and behavioural symptoms. Instructions for
identifying their own symptoms and how their
symptoms interact
Symptom identification Sleep management
Symptom formulation What to do in a mental health emergency
Working with health professionals and treatments
for chronic pain
2 2 Introduction to the basic principles of cognitive
therapy and importance of managing thoughts to
help manage not only pain but also anxiety and
depression. Instructions for monitoring and
challenging thoughts
Thought monitoring Structured problem solving and Worry Time
Thought challenging Challenging beliefs
3 1 Introduction to the physical symptoms of anxiety (ie,
hyperarousal) and depression (ie, hypoarousal) and
their relationship to emotional well-being and
managing the impact of chronic pain. Instructions
about controlling physical symptoms using de-
arousal strategies such as controlled breathing and
scheduling pleasant activities
Controlled relaxation Attention management and chronic pain
Pleasant activity scheduling Chronic pain and panic attacks
A list of 100 pleasant things to do
4 2 Introduction to the behavioural symptoms of
anxiety, low mood, and chronic pain. Explanation of
the overdoing–underdoing cycle of physical activity
and issues around the fear and the avoidance of
physical activities. Instructions for pacing and
gradually and safely increasing physical activities
Activity pacing Assertive communication
Graded exposure
5 2 Information about the occurrence of lapses in pain,
depression, and anxiety. Information about the
signs of relapse and the importance of goal setting
into the future. Instructions for creating a relapse
prevention plan and goal setting
Relapse prevention —
Goal setting
CBT, cognitive behaviour therapy.
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ongoing access to the course for the entire follow-up period and
could complete lessons and access materials after the course
had finished.
Each lesson was presented in the form of a slide show, which
took approximately 10 to 20 minutes to read, and was designed
to be easily read by someone without high school reading
proficiency. Each lesson comprised approximately 70 slides and
each slide contained approximately 100 to 200words. The lesson
materials were presented in a didactic format and included
realistic examples of skills practice and symptom management,
which were strategically integrated throughout the lessons to aid
learning. Each lesson began with a summary of the content of
previous lessons. The lessons also included summaries of key
points interspersed throughout and concepts and skills de-
scribed in previous lessons were often repeated and integrated
with novel information introduced in later lessons. Participants
had complete control over their progression through the lesson
materials and had buttons to navigate forward and backward
through the lesson slides at their own pace. Importantly, to
minimise technological requirements and maximise accessibility,
the Pain Course involves no audio or video content or interactive
or game-like treatment-related components.
Based on the findings of previous research,50,51 participants
were sent regular automated e-mails throughout the course.
Some e-mails were triggered based on participant behaviour;
specifically, e-mails were triggered when (1) participants com-
pleted a lesson during the course and when (2) participants had
not completed a lesson within 7 days of it becoming available.
E-mails were also triggered according to the course timeline;
specifically, e-mails were triggered (1) at the beginning of each
week to let participants know about newmaterials made available
that week and to suggest some tasks for participants to focus on
for the week and (2) at set times when participants were known to
commonly experience increases in symptoms or to have
increased difficulties practicing skills (eg, during the early weeks
of the course and again towards the endwhen activity pacing and
graded exposure are introduced). Each e-mail was brief and
comprised 2 to 3 paragraphs containing 3 or 4 concise
sentences. Each e-mail used the participant’s first name and
was written to convey a warm and supportive tone. Participants
were encouraged to complete 1 lesson every 7 to 10 days and to
attempt to regularly practice the skills covered within the lesson
summaries.
2.4. Clinical contact
Two registered psychologists (M.G. and L.J.) with postgraduate
qualifications in psychology and several years of clinical
experience provided all clinical contact with participants, which
occurred through telephone or a secure e-mail system. Neither
psychologist had significant previous clinical experience working
with patients with chronic pain. B. F. Dear provided scheduled
and weekly, 1 hour, supervision sessions to both psychologists
during which all participants were reviewed. Supervision was
provided at other times as required. B. F. Dear is a registered
clinical psychologist with more than 7 years of clinical experience
in the area of chronic pain. The details of contact with all
participants were recorded.
Participants in the Regular Contact Group and the Optional
Contact Groupwere assigned to one of the clinicians for the entire
course. Clinicians aimed to provideweekly contact to participants
in the Regular Contact Group, through telephone or secure
e-mail, for a period of between 10 to 15 minutes per contact
unless more contact was clinically required. Participants in the
Optional Contact Group were also informed that their clinician
was available for around 10 to 15minutes each week and that the
participant could contact the clinician on an “as-needed” basis
throughout the course. However, they were informed that the
clinician would not attempt to contact them without an explicit
request for contact. Clinicians provided the same kind of clinical
contact to participants in the Regular Contact and the Optional
Contact Groups; the only difference was that the clinicians did not
attempt to initiate contact with the participants in the Optional
Contact Group each week as they did with the participants in the
Regular Contact Group. Participants in the No Contact Group
were informed that they were in a group who would not receive
contact during the course unless they experienced technical
difficulties or a mental health emergency. The questionnaire
responses of participants in the No Contact Group were
monitored twice daily, alongside the other Treatment Groups,
throughout the course but contact was only initiated if a de-
terioration in their mental health (ie, defined as an increase in the
PHQ-9 total score of $5 with a total score $15) was observed.
This contact involved the administration of a risk assessment and,
if needed, referral to appropriate crisis services.
The primary purpose of clinician contact was to encourage and
support participants to work through the Pain Course and to
apply the skills in the context of their symptoms and circum-
stances; rather than providing psychological treatment them-
selves. Importantly, in accordance with previous research,15,26
clinicians were instructed to: (1) answer participants’ questions;
(2) summarise content; (3) encourage skills practice and reinforce
progress; (4) enquire about participants’ experiences with the
course and use of the skills; and (5) normalise challenges in the
learning and use of the core skills. Clinicians were instructed not
to introduce new therapeutic skills not covered within the course
and, unless clinically indicated, to limit the time spent in contact or
contacting participants to approximately 10 to 15 minutes per
week. Clinicians were instructed not to request participants to
submit examples of their use of the skills or completed
worksheets for evaluation or checking. However, the clinicians
did provide feedback on skills use and worksheet completion
where it was requested by participants.
2.5. Analytic plan
All analyses were conducted using SPSS version 21. Group
differences in demographic and pain-related variables were
analysed using x2 tests, nonparametric Mann–Whitney U tests,
and parametric 1-way analyses of variance. The alpha signifi-
cance level for the preliminary analyses was adjusted from 0.05 to
0.01 as a partial control for the very large number of analyses
conducted. Chi-square analyses were not reported where any
cell comprised n # 5.
A generalised estimation equation (GEE) modelling technique
was used to examine changes in the measures over time.
Generalised estimation equation emphasizes the modelling of
change in an average group effect over time while accounting for
within-subject variance with the specification of a working
correlation structure. Rather than creating conditional interpreta-
tion with the use of individual intercepts or random slopes, as in
traditional mixed linear models, the primary emphasis in GEE is to
directly model the average group-related change over time.25 The
GEE analyses therefore provide model coefficients that represent
multiplicative change in the dependent variable, and these
coefficients form a change factor (ie, exp(b)), which can be used
to calculate the average percentage change from baseline to any
time point for each group. An exchangeable working correlation
1926 B.F. Dear et al.·156 (2015) 1920–1935 PAIN®
  
structure was selected, coupledwith a robust error estimation, for
all GEE analyses. All GEE models also specified a gamma
distribution with a log link response scale to address skewness in
the dependent variable distributions. Importantly, initial assess-
ment was used as baseline for the primary and secondary
outcomes in all analyses concerning the primary and secondary
outcomes. However, because there was a 1- to 8-week period
between initial assessment and pretreatment, the pretreatment
data are also presented for the primary and secondary outcomes
to demonstrate their stability before treatment. For the tertiary
outcomes, which were not assessed at initial assessment,
pretreatment is used as baseline for all analyses. Separate
generalised linear models, utilising time effects and random
intercepts, were used to impute missing data in the dependent
variables consistent with intention-to-treat principles. Then, to
compare the relative outcomes of the 4 groups, GEE analyses
were run comparing the primary and secondary outcome
variables from initial assessment to pretreatment, posttreatment
and 3-month follow-up. SPSS pairwise comparisons were used
to explore and understand any significant main and interaction
effects observed in the GEE analyses.
Several different statistics were calculated for comparison
and benchmarking purposes. First, the average percentage
change across time was calculated from the GEE analyses for
each of the outcome variables with 95% confidence intervals.
Second, Cohen’s d effect sizes and 95% confidence intervals
were also calculated for the between-group effects based on
the estimated marginal mean values derived from the GEE
models. Third, based on previous recommendations33,39 and
consistent with the initial trial,15 the percentage of participants
in each group reporting improvements in symptoms of $10%,
20%, 30%, 40%, and 50% and the numbers needed to treat
(NNT) to obtain each banding of change are reported. The NNT
was calculated using the formula, NNT 5 1/ARR, where ARR
(Absolute Risk Reduction)5CER (Control Group Event Rate)2
TER (Treatment Group Event Rate). Chi-square tests were used
to examine differences between the Treatment Groups in the
number of participants reporting improvements at posttreat-
ment and 3-month follow-up.
To provide data about negative outcomes45 and consistent
with the previous trial,15 the number of participants reporting
symptom deteriorations $30% and symptoms in the clinical
ranges at posttreatment (ie, above recognised clinical cutoffs) on
the primary outcome measures are also reported. The clinical
ranges were defined as total scores$8 on the GAD-7,46 $10 on
the PHQ-9,29 $14 on the RMDQ,35 and $6 on the average pain
item of the WBPQ.35 The clinical cutoffs used for the GAD-7 and
PHQ-9 have been previously identified as indicating probable
diagnoses of an anxiety disorder and depressive disorder.29,46
However, because of the absence of an established cutoff, the
50th percentile of all scores of patients presenting to a tertiary
pain service was used as the cutoff for the RMDQ and WBPQ.35
Importantly, these analyses are designed not to capture
participants whose scores may have increased by $30% but
who, despite the increase, still have nonclinical symptoms. Thus,
these analyses were designed not to include fluctuations in
scores that are unlikely to represent an actual or meaningful
deterioration in symptoms (eg, a change in score from 0 to 1).
The GEE analyses were also used to examine self-reported
prescription medication use, health service use and changes in
vocational status from pretreatment to posttreatment and
3-month follow-up. These GEE analyses for medication use,
which was coded as a binary yes or no, used a suitable negative
binomial distribution for the probability of observing medication
use over time. The GEE analyses for vocational status also used
a binary yes or no response employing a binomial distribution for
the probability of observing a change over time. These GEE
analyses for medication use, service use and vocational status
were conducted only on the observed data; that is, no imputation
was used for missing data given the absence of an accepted
protocol within the literature. For service use data, significant
atypical and outlying responses, that is, those responses more
than $5 SDs from the group mean or that were well outside the
observed distribution of responses, were removed. These cases
were removed to provide a more accurate and representative
group-based estimate of service use over time. Some medica-
tion, health professional and vocational categories were also
either not analysed or were combined due to very low use.
3. Results
3.1. Baseline data, adherence, and attrition
The demographic and pain-related characteristics of the
sample are shown in Tables 1 and 2. Specific details of
participant flow, treatment attrition, lesson completion, and
questionnaire response are shown in Figure 1. One-way
analyses of variance and x2 tests did not identify any significant
differences between the Treatment and Control Groups on the
demographic variables (Ps . 0.01). No differences were found
between the number of lessons completed by the Treatment
Groups at either posttreatment or 3-month follow-up (P . 0.01).
Bonferroni-corrected comparisons revealed no significant differ-
ences between participants completing and not completing the
questionnaires across the groups at posttreatment in terms of age
(Ps . 0.01), pain duration (Ps . 0.01), number of pain sites
(Ps. 0.01), average pain (Ps. 0.01), and initial PHQ-9, GAD-7, or
RMDQ scores (Ps . 0.01).
3.2. Primary outcomes for the overall samples
The primary outcomes were disability, depression, and anxiety,
which were assessed using RMDQ, PHQ-9, and GAD-7,
respectively. The mean values, SDs, percentage reductions,
and Cohen’s d effect sizes for the 4 groups and the primary,
secondary, and tertiary outcome variables are shown in Table 4.
The GEE analyses revealed significant effects for Time (Disability:
Wald’s x2 5 280.90, P , 0.001; Depression: Wald’s x2 5
353.18, P, 0.001; Anxiety: Wald’s x25 240.23, P, 0.001) and
significant Time by Group interactions (Disability: Wald’s x2 5
61.95, P , 0.001; Depression: Wald’s x2 5 144.73, P , 0.001;
Anxiety: Wald’s x2 5 83.29, P , 0.001). Planned contrasts
revealed no significant differences between the groups at
assessment (P range: 0.118-0.916). However, across the primary
outcomes, planned contrasts revealed significant reductions
from assessment to posttreatment for the Treatment Groups
(Ps , 0.001) and not the Control Group (P range: 0.244-0.978).
The contrasts revealed the Treatment Groups had significantly
lower scores posttreatment compared with the Control Group
(Ps # 0.003) and no differences between the Treatment Groups
(P range: 0.132-0.890). The contrasts also revealed that both the
depression and anxiety scores of the Regular Contact Group
increased slightly from posttreatment to 3-month follow-up
(P # 0.003), while the Optional Contact Group’s anxiety scores
decreased slightly from posttreatment to 3-month follow-up
(P 5 0.032) and that the 3 Treatment Groups all made further
improvements from posttreatment to follow-up in their disability
levels (Ps# 0.003). However, there were no differences between
October 2015·Volume 156·Number 10 www.painjournalonline.com 1927
  
Table 4
Mean values, SDs, percentage change, and effect sizes for the primary, secondary, and tertiary outcome measures.
n Estimated marginal mean values Percentage change from baseline* Between-group Cohen’s d effect sizes at posttreatment
Initial
application
Pretreatment Posttreatment 3 month
follow-up




Optional Contact No Contact Waitlist Control
Primary outcomes
Disability (RMDQ)
Regular Contact 139 13.92 (5.08) 13.47 (5.23) 11.05 (5.63) 10.01 (5.78) 3 (23 to 9) 21 (14 to 27) 28 (21 to 35) — 20.02 (20.25 to
0.22)
0.06 (20.19 to 0.30) 0.53 (0.24 to 0.82)
Optional Contact 135 13.43 (5.17) 13.24 (5.60) 10.95 (5.84) 10.05 (5.85) 1 (26 to 8) 18 (11 to 25) 25 (17 to 32) — — 0.07 (20.17 to 0.32) 0.54 (0.25 to 0.82)
No Contact 123 14.22 (4.76) 13.92 (5.06) 11.36 (5.22) 10.40 (5.37) 2 (24 to 8) 20 (13 to 26) 27 (21 to 33) — — — 0.50 (0.21 to 0.79)
Waitlist Control 74 14.35 (4.95) 13.93 (5.22) 13.97 (5.17) — 3 (26 to 11) 3 (26 to 11) — — — — —
Depression (PHQ-9)
Regular Contact 139 11.25 (4.86) 11.55 (5.88) 6.30 (4.57) 7.49 (5.09) 23 (212 to 6) 44 (37 to 50 33 (25 to 41) — 0.18 (20.05 to
0.42)
0.15 (20.09 to 0.39) 0.98 (0.68 to 1.27)
Optional Contact 135 11.19 (5.48) 10.60 (5.33) 7.20 (5.25) 7.01 (4.71) 5 (23 to 13) 36 (27 to 43) 37 (30 to 44) — — 20.05 (20.29 to
0.19)
0.73 (0.44 to 1.02)
No Contact 123 11.32 (4.89) 10.90 (4.76) 6.96 (4.29) 7.08 (4.32) 4 (24 to 11) 39 (31 to 45) 37 (30 to 44) — — — 0.87 (0.56 to 1.16)
Waitlist Control 74 11.04 (5.25) 10.37 (5.47) 11.11 (5.51) — 6 (26 to 17) 21 (213 to 10) — — — — —
Anxiety (GAD-7)
Regular Contact 139 9.00 (5.37) 8.40 (5.52) 4.91 (4.40) 5.67 (4.83) 7 (24 to 16) 45 (37 to 53) 37 (27 to 45) — 0.16 (20.08 to
0.40)
0.06 (20.18 to 0.30) 0.63 (0.34 to 0.92)
Optional Contact 135 8.28 (4.81) 7.98 (4.67) 5.66 (4.94) 4.99 (3.89) 4 (26 to 13) 32 (21 to 41) 40 (31 to 47) — — 20.11 (20.36 to
0.13)
0.44 (0.15 to 0.73)
No Contact 123 8.01 (4.79) 8.28 (4.60) 5.16 (3.91) 4.92 (3.72) 23 (214 to 6) 36 (26 to 44) 39 (30 to 46) — — — 0.61 (0.31 to 0.90)




Regular Contact 139 5.70 (1.61) 5.74 (1.72) 4.86 (1.79) 4.96 (2.00) 21 (26 to 4) 15 (9 to 20) 13 (7 to 19) — 20.01 (20.24 to
0.23)
0.19 (20.05 to 0.43) 0.50 (0.21 to 0.79)
Optional Contact 135 5.70 (1.46) 5.54 (1.74) 4.85 (1.73) 4.68 (1.87) 3 (22 to 8) 15 (10 to 20) 18 (12 to 23) — — 0.20 (20.05 to 0.44) 0.52 (0.23 to 0.81)
No Contact 123 5.90 (1.53) 5.72 (1.63) 5.20 (1.80) 5.02 (1.93) 3 (22 to 8) 12 (6 to 17) 15 (9 to 21) — — — 0.30 (0.01 to 0.59)








20.49 (20.78 to 2
0.21)
Optional Contact 135 — 28.61 (14.08) 33.60 (13.83) 34.53 (12.96) — 15 (9 to 21) 17 (11 to 22) — — 20.03 (20.27 to
0.21)
20.30 (20.58 to 2
0.01)
No Contact 123 — 26.80 (11.52) 33.21 (11.97) 33.99 (12.66) — 19 (14 to 24) 21 (16 to 26) — — — 20.29 (20.58 to
0.00)
Waitlist Control 74 — 28.63 (12.10) 29.68 (12.11) — — 4 (26 to 12) — — — — —
Fear of movement
(TSK)




































the Treatment Groups on the primary outcomes at follow-up
(P range: 0.154-0.958).
3.3. Secondary outcome for the overall samples
The secondary outcome was average pain, which was
assessed using the average pain item of the WBPQ. The GEE
analyses revealed significant effects for Time (Average pain:
Wald’s x25 174.40, P, 0.001) and a significant Time by Group
interaction (Average pain: Wald’s x2 5 25.31, P 5 0.001).
Planned contrasts revealed no significant differences between
the groups at assessment (P range: 0.150-0.994) and that
average pain scores significantly reduced from assessment to
posttreatment for the Control Group (P 5 0.020) and the 3
Treatment Groups (Ps , 0.001). However, despite all groups
improving, planned contrasts indicated that the 3 Treatment
Groups had significantly lower average pain scores than the
Control Group at posttreatment (Ps# 0.03) and that there were
no differences between the Treatment Group pain ratings at
posttreatment (P range: 0.111-0.933) or 3-month follow-up
(P range: 0.146-0.780).
3.4. Tertiary outcomes for the overall samples
The tertiary outcomes were pain self-efficacy, fear of move-
ment, and pain acceptance, which were assessed using PSEQ,
TSK, and CPAQ-8, respectively. The GEE analyses revealed
significant effects for Time (Pain self-efficacy: Wald’s x2 5
167.90, P , 0.001; Fear of movement: Wald’s x2 5 196.43,
P , 0.001; Pain acceptance: Wald’s x2 5 184.84, P , 0.001)
and significant Time by Group interactions (Pain self-efficacy:
Wald’s x2 5 27.41, P, 0.001; Fear of movement: Wald’s x2 5
19.17, P 5 0.002; Pain acceptance: Wald’s x2 5 24.73, P ,
0.001). Planned contrasts revealed no significant differences
between the groups at pretreatment on the tertiary outcomes
(P range: 0.075-0.991). However, planned contrasts revealed
significant improvements from pretreatment to posttreatment
for the Treatment Groups across the outcomes (Ps . 0.001),
but not for the Control Group (P range: 0.067-0.198), which
only exhibited significant improvements in their fear of
movement (P 5 0.004). The 3 Treatment Groups all had
significantly improved pain self-efficacy and fear of movement
scores compared with the Control Group (Ps # 0.046), and
there were no differences between the Treatment Groups at
posttreatment (P range: 0.078-0.895). Comparisons revealed
that there were no differences between the Treatment Groups
on fear of movement at 3-month follow-up (P range: 0.125-
0.531) or pain self-efficacy (P range: 0.107-0.740), except for
the No Contact Group, which reported marginally lower levels
of pain self-efficacy compared with the Regular Contact Group
(P5 0.048). The contrasts revealed no differences between the
Treatment Groups on pain acceptance at posttreatment
(P range: 0.120-0.695) and that only the Regular Contact
Group had significantly higher scores than the Control Group
(P 5 0.003). However, at 3-month follow-up, the Regular
Contact Group had marginally superior scores to the No
Contact Group (P 5 0.031) with no other differences between
the Treatment Groups observed (P range: 0.158-0.490).
3.5. Clinical significance analyses
The percentage change estimates from the GEE models and
between-group effect sizes for the outcomes at posttreatment
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found for disability (range: 18%-21%), depression (range: 36%-
44%), anxiety (range: 32%-45%), and average pain (range: 12%-
15%) across the treatment groups immediately posttreatment,
which were maintained or further improved to 3-month follow-up
(Disability: 25%-28%; Depression: 33%-37%; Anxiety: 37%-
40%; Average pain: 13%-18%). Large between-group effect
sizes (Cohen’s d) were found for depression (d range: 0.73-0.98)
and moderate between-group effect sizes for anxiety (d range:
0.44-0.63) and disability (d range: 0.50-0.54) for the Treatment
Groups, relative to control, at posttreatment. Small-to-moderate
between-group effect sizes were found for average pain levels (d
range: 0.30-0.52) among the Treatment Groups, relative to
control, at posttreatment.
The number of participants with scores on the primary and
secondary outcomes improving by $10%, 20%, 30%, 40%,
and 50% at posttreatment and follow-up is shown in Table 5.
The NNT for the outcomes at posttreatment are also presented
in Table 5. With 2 exceptions, no differences were found
between the Treatment Groups in the proportions of partic-
ipants improving (ie, $10%, 20%, 30%, 40%, and 50%) in
disability, depression, anxiety, and average pain at posttreat-
ment (x2 , 5.73; P . 0.05). One significant difference was
observed between the Treatment Groups in the proportions
reporting improvements $10% in depression (x2 5 6.39; P 5
0.041), where the Regular Contact Group had a greater
proportion of participants reporting improvements $10%
compared with the No Contact Group at posttreatment.
Another significant difference was observed between the
Treatment Groups in the proportions reporting improvements
$50% in depression (x2 5 7.89; P5 0.019), where the Regular
Contact Group had a greater proportion of participants
reporting improvements $50% compared with the No Contact
Group and Optional Contact Group at posttreatment. However,
no differences were observed between the Treatment Groups at
3-month follow-up (x2 , 5.41; P . 0.05).
3.6. Clinical deterioration
Two percent (4/139), 2% (3/135), 1% (1/123), and 9% (7/74) in
the Regular Contact, Optional Contact, No Contact, and Waitlist
Control Groups, respectively, reported increases in disability
scores $30% and scored within the clinical ranges at posttreat-
ment. Three percent (5/139), 6% (9/135), 7% (9/123), and 14%
(11/74) in the Regular Contact, Optional Contact, No Contact,
and Waitlist Control Groups, respectively, reported increases in
anxiety scores $30% and scored within the clinical ranges at
posttreatment. Three percent (5/139), 5% (7/135), 3% (4/123),
and 17% (13/74) of participants in the Regular Contact, Optional
Contact, No Contact, and Waitlist Control Groups, respectively,
reported increases in depression scores $30% and scored
within the clinical ranges at posttreatment. Finally, 2% (4/139),
2% (3/135), 2% (3/123), and 4% (3/74) of participants in the
Regular Contact, Optional Contact, No Contact, and Waitlist
Control Groups, respectively, reported increases in average pain
$30% and scored within the clinical ranges at posttreatment.
Overall, participants in the Treatment Groups reported signifi-
cantly fewer instances of deterioration in disability, depression,
and anxiety compared with the Control Group (x2 range: 7.66-
19.78; P# 0.006), but not in average pain levels (x2 5 0.54; P5
0.459). No participants reported that the program caused clinical
deteriorations in symptoms.
3.7. Prescription medication and health service use
Prescription medication use, health service use, and vocational
status data for each group across the time points are shown in
Table 5
Percentages reporting ‡10, 20, 30, 40, and 50% improvements and the NNT to obtain improvements.

































Regular Contact 139 63 77 3.2 53 64 3.2 34 50 4.1 21 27 5.8 15 23 8.3
Optional Contact 135 64 72 3.1 50 60 3.5 34 46 4.1 21 27 5.8 14 20 9.0
No Contact 123 63 72 3.2 47 64 4.0 32 46 4.5 20 27 6.2 11 19 12.5
Waitlist Control 74 32 — — 22 — — 10 — — 4 — — 3 — —
Depression (PHQ-9)
Regular Contact 139 81 78 2.7 72 70 2.1 70 55 1.7 62 45 1.8 46 35 2.3
Optional Contact 135 71 81 3.8 65 70 2.5 60 60 2.1 56 52 2.0 34 36 3.2
No Contact 123 83 84 2.6 75 77 2.0 63 70 2.0 47 50 2.5 30 26 3.7
Waitlist Control 74 45 — — 26 — — 14 — — 8 — — 3 — —
Anxiety (GAD-7)
Regular Contact 139 78 68 2.6 70 63 2.7 65 55 2.4 57 48 2.5 48 38 3.0
Optional Contact 135 67 76 3.7 60 68 3.8 54 63 3.3 45 51 3.7 40 38 4.0
No Contact 123 70 72 3.3 66 68 3.1 58 60 2.9 50 55 3.1 33 43 5.5




Regular Contact 139 63 58 4 36 32 5.5 19 24 9.0 12 16 8.3 7 8 14.2
Optional Contact 135 57 64 5.2 39 39 4.7 25 27 5.8 11 17 9.0 5 10 20.0
No Contact 123 56 65 5.5 30 37 8.3 19 24 9.0 9 13 11.1 5 7 20.0
Waitlist Control 74 38 — — 18 — — 8 — — 0 — — 0 — —
NNT calculated using NNT 5 1/ARR, where ARR 5 CER 2 TER.
Percentages are rounded to the nearest whole number. NNTs are not rounded.
ARR, absolute risk reduction; CER, control group event rate; GAD-7, Generalized Anxiety Disorder 7-item Scale; NNT, number needed to treat; PHQ-9, Patient Health Questionnaire 9-item; RMDQ, Roland–Morris Disability
Questionnaire; TER, treatment group event rate; WBPQ, Wisconsin Brief Pain Questionnaire.
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Table 6. The GEE analyses revealed significant effects for Time
on strong opioid use (Wald’s x25 11.45,P5 0.003), weak opioid
use (Wald’s x2 5 17.69, P , 0.001), nonsteroidal anti-
inflammatory use (Wald’s x25 7.09, P5 0.029), benzodiazepine
use (Wald’s x2 5 13.38, P 5 0.001), and antidepressant and
anxiolytic use (Wald’s x2 5 16.54, P , 0.001), but no Time by
Group interactions for these medications (strong opioids: Wald’s
x2 5 4.34, P 5 0.502; weak opioids: Wald’s x2 5 6.16, P 5
0.291; nonsteroidal anti-inflammatories: Wald’s x2 5 4.99, P 5
0.417; benzodiazepines: Wald’s x2 5 4.31, P 5 0.431;
antidepressants and anxiolytics: Wald’s x2 5 4.31, P 5 0.506).
Overall, these analyses indicated that use of these medications
reduced by up to 29% from pretreatment to 3-month follow-up
across the groups.
The GEE analyses revealed significant effects for Time on visits to
general practitioners (Wald’s x2 5 31.23, P , 0.001), medical
specialists (Wald’sx2516.60,P, 0.001), physiotherapists (Wald’s
x25 12.83, P5 0.002) and use of telephone crisis and emergency
department services (Wald’s x25 8.44,P5 0.015), but only a Time
by Group interaction for visits to medical specialists (Wald’s x2 5
13.09, P 5 0.022). Pairwise comparisons revealed that the rate of
reduction in visits to medical specialists was marginally greater
among the Optional Contact and No Contact groups compared
with the Control Group (Ps, 0.034), but there were no differences
between the Treatment Groups at 3-month follow-up (Ps. 0.079).
Overall, the analyses indicated that use of general practitioner,
medical specialist, physiotherapist, and telephone crisis and
emergency department services reduced by up to 41% from
pretreatment to 3-month follow-up across the groups.
The GEE analyses did not reveal any significant effects for Time
or Time by Group interactions for full-time work (Wald’s x2 ,
9.34, P . 0.095), part-time and casual work (Wald’s x2 , 5.34,
P. 0.096), full-time and part-time study (Wald’s x2 , 4.20, P.
0.188), unemployment and seeking work (Wald’s x2, 3.66, P.
0.284), or registered as disabled (Wald’s x2 , 4.85, P . 0.088).
However, a marginally significant effect for Time was found for
retirement (Wald’s x2 5 6.45, P5 0.040), but no Time by Group
interaction was found (Wald’s x2 5 8.37, P 5 0.137). Pairwise
comparisons revealed that there was a significant overall increase
in the number of participants reporting themselves as retired at
3-month follow-up (P 5 0.011).
3.8. Treatment satisfaction
Of the participants completing the treatment satisfaction ques-
tions, 92% (108/117), 82% (102/123), and 89% (89/100) of
participants in the Regular Contact, Optional Contact, and No
Contact Groups, respectively, reported being “satisfied” or “very
satisfied” with the course. Similarly, 96% (113/117), 95% (118/
123), and 97% (97/100) of participants in the Regular Contact,
Optional Contact, andNoContact Groups, respectively, reported
that they “would recommend the course” to others. Moreover,
96% (113/117), 92% (114/123), and 95% (95/100) of participants
in the Regular Contact, Optional Contact, and No Contact
Groups, respectively, reported that “the course was worth their
time.” There were no significant differences between the groups
in the proportions of participants being satisfied with the course,
being willing to recommend the course or finding the course was
worth their time (x2 range: 0.19-5.12; P . 0.05).
3.9. Time spent and summary of contacts
Significant differences were found between the Treatment
Groups in the amount of clinician time required (F 5 240.67,
P , 0.001) with the Regular Contact Group requiring more time
than both the Optional Contact and No Contact Groups (P ,
0.001) and the No Contact Group requiring less time than the
Optional Contact Group (P5 0.02). The mean total clinician time
per participant for the Regular Contact Group over the 8 weeks of
the course was 67.69 minutes (SD 5 33.50), which comprised
answering and making calls (Total5 890; M5 6.40; SD5 2.84;
range: 1-12) as well as reading, sending, and responding to
secure e-mails (Total5 783; M5 5.63; SD5 2.39; range: 0-11).
Fifty-six percent (76/135) and 39% (48/123) of participants in the
Optional Contact and No Contact Groups received 1 or more
contacts through e-mail or telephone during the course, re-
spectively. The mean total clinician time per participant for the
Optional Contact Group was 12.85 minutes (SD5 24.61), which
comprised answering and making calls (Total 5 100; M 5 0.74;
SD 5 1.28; range: 0-8) as well as reading, sending, and
responding to secure e-mails (Total 5 104; M 5 0.77; SD 5
1.08; range: 0-5). The mean total clinician time per participant in
the No Contact Group was 5.44 minutes (SD 5 12.38), which
comprised answering and making calls (Total 5 30; M 5 0.24;
SD 5 0.657; range: 0-4) as well as reading, sending, and
responding to e-mails (Total 5 75; M 5 0.61; SD5 1.02; range:
0-4). However, this contact was focussed on assessing and
managing mental health crises rather than the provision of
treatment or course-related clinical support. An additional 20.34
minutes (SD 5 6.66; range: 5 minutes to 50 minutes) was
required on average per participant to conduct the initial
assessment through telephone before participation in the course.
4. Discussion
The present study sought to replicate the results of an earlier trial
of a new internet-delivered pain management program and to
explore its efficacy when provided with different levels of clinical
support. It was hypothesised that all Treatment Groups would
report improvements on clinical measures of anxiety, depression,
and disability relative to a Control Group and that those
participants receiving regular clinician contact would exhibit
superior outcomes. These hypotheses were partially supported.
All 3 Treatment Groups reported significant improvements
(between-group Cohen’s d; avg. reduction) in disability (ds $
0.50; avg. reduction$ 18%), anxiety (ds$ 0.44; avg. reduction$
32%), depression (ds$ 0.73; avg. reduction$ 36%) and average
pain (ds $ 0.30; avg. reduction $ 12%) immediately posttreat-
ment, which were sustained or further improved to 3-month
follow-up. No marked or consistent differences emerged
between the Treatment Groups in clinical outcomes. Treatment
completion and satisfaction rates were also high and did not differ
across the Treatment Groups.
These findings replicate those of the initial trial15 and compare
favourably with those reported for other internet-delivered3,19,32
and face-to-face pain management programs.11,21,40 For exam-
ple, a recent Cochrane review of internet-delivered programs
found evidence of moderate effect sizes for disability (d 5 0.50)
and small effects for anxiety (d 5 0.19) and depression (d 5
0.19),19 where the current study found moderate-to-large effect
sizes for the primary outcomes of disability, anxiety, and
depression (all ds $ 0.44; avg. reductions $ 18%) immediately
posttreatment. The present study also found small-to-moderate
effect sizes for the secondary outcome of average pain (all ds $
0.30; avg. reductions$ 12%) consistent with the recent review19
and small-to-moderate effect size improvements on the tertiary
outcomes of pain self-efficacy (d $ 20.29; avg. increases $
15%), fear of movement (d $ 0.34; avg. decreases $ 7%), and
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Table 6
Prescription medication use, health service use, and vocational status with estimates of relative change from pretreatment to posttreatment and 3-month follow-up.


























Overall Pre to post Pre to follow-up





27 26 28 43 30 24 24 23 37 26 20 21 23 — 21 212 (221 to 22) 223 (234 to 211)
Weak opioid
analgesics
27 30 31 35 30 20 24 27 31 25 19 23 31 — 24 225 (236 to 29) 226 (236 to 214)
Nonsteroidal anti-
inflammatories
19 22 23 23 22 18 15 18 22 18 17 17 22 — 18 222 (235 to 26) 219 (235 to 26)
Anticonvulsants 27 23 29 35 28 29 21 27 34 27 30 26 27 — 28 26 (217 to 6) 22 (215 to 15)
Benzodiazepines 15 16 13 26 16 11 13 11 22 13 13 10 12 — 12 227 (239 to 212) 229 (244 to 210)
Anxiolytics and
antidepressants























































































































































12 (219 to 57) 241 (262 to 26)
Employment/vocational
status‡, %
Full-time employment 28 21 22 17 23 22 24 21 17 21 25 22 21 — 23 26 (217 to 5) 0 (213 to 13)
Part-time/casual
employment
23 32 24 28 27 26 30 24 35 28 23 27 21 — 24 24 (220 to 11) 9 (27 to 24)
Full-time/part-time
student
9 9 11 8 9 12 9 13 11 11 13 7 10 — 10 221 (257 to 7) 28 (245 to 21)
Unemployed/seeking
work
16 20 15 12 16 13 14 16 13 14 11 18 15 — 14 15 (27 to 33) 13 (211 to 33)
Registered disability 19 21 22 27 22 19 22 21 24 21 16 17 21 — 18 25 (220 to 14) 220 (234 to 23)
Retired 21 14 17 20 19 26 15 23 25 22 26 13 26 — 21 14 (21 to 31) 20 (4 to 39)
Percentages, SEs, and 95% confidence intervals are shown in parentheses. All data were self-reported. Percentages are rounded to the nearest whole number.
* The overall estimates of relative change are derived from the GEE model, which combined the 3 Treatment Groups and the Control Group as only a significant time effect was found across the outcomes.
† Only prescription medications for pain, a pain-related condition, anxiety, or depression are reported. Strong opioids: buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone; weak opioids: codeine, tramadol, tapentadol; anxiolytics and antidepressants: beta blockers, selective serotonin
reuptake inhibitors, norepinephrine and serotonin–norepinephrine reuptake inhibitors, tricyclics and tetracyclics.
‡ Categories of employment and vocational status were not mutually exclusive; participants could indicate more than one to best describe their situation.




































pain acceptance (d $20.22; avg. increases $ 8%), which have
been identified as important targets of CBT-based pain man-
agement programs.36,37 The present study also found evidence
of significant reductions inmedication use and health service use,
but these were observed across the Treatment and Control
Groups. These clinical outcomes were obtained with a mean
clinician time per participant of 67.69 minutes (SD 5 33.50),
12.85 minutes (SD 5 24.61), and 5.44 minutes (SD 5 12.38) for
participants receiving regular contact, optional contact, and no
clinical contact, respectively. The clinician time required for the
Regular Contact Group was less than the previous trial (81.54
minutes; SD5 30.91),15 which may reflect reduced demands for
clinician contact following iterative revisions to the Pain Course
since the initial trial. Importantly, consistent with findings of trials in
other areas (eg, 4,5,50,51), these findings suggest that good
clinical outcomes can be obtained by internet-delivered pro-
grams involving very little or nonclinical contact. This is consistent
with a recent review, which concluded that, following a screening
procedure and provided the content is of a high quality and is
sufficiently engaging for patients, clinician expertise and timemay
be less important in internet-delivered than face-to-face
interventions.2
More research is needed to explore the characteristics of
people who do and do not benefit from internet-delivered
programs. The findings of the current study are encouraging
with, for example, the demographic and pain characteristics of
participants in this study appearing similar to those of patients
attending face-to-face pain management programs (eg, 36,37),
except that a larger proportion had higher levels of education.
Given the considerable variability in the findings of existing
studies,3,19,32 there is also a need for more research to explore
the essential components and parameters of effective, safe, and
acceptable internet-delivered programs. For example, while the
current program obtained high completion rates and levels of
satisfaction, many internet-delivered programs have reported
significant levels of participant dropout and program non-
completion (eg,.50% in some cases) (eg, 18,47). It is noteworthy
that, while often thought to be essential components of internet-
delivered interventions, the present study obtained very good
outcomes without any audio or video content and without any
interactive treatment-related components. Thus, more research
is needed to understand the essential components of effective
internet-delivered programs and when and for whom these
programs are effective. This is essential to guide the integration of
internet-delivered pain management programs into existing
health care systems.
There are a number of limitations that need to be considered in
the present study. First, the use of a treatment-as-usual Waitlist
Control Group design limits our ability to control for nonspecific
therapeutic effects and leaves open the possibility that partic-
ipants in the Control Group may have recovered without
treatment. However, it is important to note that participants had
marked difficulties with chronic pain that were unlikely to
spontaneously remit and, in fact, the Control Group reported
a significant number of symptom deteriorations while on the
waitlist. It is also important to note that, as there is now evidence
for efficacy of the Pain Course it is becoming increasingly difficult
to obtain ethical approval for research designs (eg, attention
control designs, noncrossover longitudinal control designs) that
do not involve timely access to either the Pain Course or some
other equivalent active treatment, thus, limiting the designs the
research team could use in the present study. Second, while
longer term follow-up is planned and will be reported in the future,
it is currently unclear whether the current results will be
maintained over the longer term. Third, participants were not
restricted in the treatments they could receive during the trial and
so participants started, changed, and stopped various treat-
ments during the trial. Unfortunately, this means that it is not
possible to completely rule out the positive and negative effects of
other treatments in the current trial, although the use of
a treatment-as-usual Waitlist Control Group means that these
other treatments were at least partially controlled and are unlikely
to have affected the major outcomes. Fourth, participants in the
present study sought to participate in a pain management
program and, consequently, it is unclear how the results would
generalise to patients who were not seeking such a program.
Fifth, while prescription medications use, health service use and
vocational status were examined, the present study relied on self-
report data. Sixth, it is unclear from the current study how
important the observed changes in the tertiary outcomes, which
are believed to be important psychological targets of face-to-face
pain management programs, are to the improvements in the
primary outcome variables. Further research is needed to explore
whether these and other tertiary psychological outcomes are as
important to internet-delivered treatments as has been sug-
gested and observed in some face-to-face pain management
programs.36,37 Finally, the aim of the present study was to
examine the overall efficacy of an internet-delivered pain
management program provided with 3 levels of clinical support
rather than comprehensively examine the characteristic of people
who benefit from these programs. Thus, future research is
needed to focus on the characteristics of participants who are
suitable for and benefit from internet-delivered and face-to-face
pain management programs.
The present study has a number of notable strengths. First, it
is the largest in the literature to explore an internet-delivered pain
management program and to directly compare several different
models of support. Second, it directly replicates an earlier trial
and, consistent with the initial trial,15 obtained high question-
naire response rates, providing confidence in the outcomes
observed. Third, it included a heterogeneous group of partic-
ipants with chronic pain including participants reporting pain as
a result of various pain conditions, injuries, medical treatments
as well as a broad range of other significant health conditions
(eg, cancer, multiple sclerosis, epilepsy, diabetes, spinal cord
injuries). Fourth, it is the first study of an internet-delivered
program for chronic pain to examine medication use, health
service use and vocational status over time. Fifth, it is one of
a very limited number to report on the acceptability of the
program and to report on negative outcomes and symptom
deterioration.19 Notably, the number of symptom deteriorations
was significantly less among the Treatment Groups and no
participants identified the program as the cause of their
deterioration. Finally, it employed standardized and widely used
clinical measures and assessed across the outcome domains
targeted by pain management interventions (ie, disability,
anxiety, and depression) and provides a broad range of data
in several widely used formats and clinical metrics to enable
benchmarking and comparison of outcomes.33,39
In summary, the present study replicates and extends the
findings of an earlier trial. Significant improvements in levels of
disability, anxiety, depression, and pain were observed and no
consistent or marked differences were found across the levels of
clinician support provided. More research is needed to realise the
potential of internet-delivered pain management programs and
properly understand the participant, treatment and other factors
affecting clinical efficacy, safety, and acceptability. However,
while caution and further research is needed, the findings of the
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present study add to the existing literature in highlighting the very
significant potential of carefully developed and administered
internet-delivered pain management programs as a way of
increasing access to evidence-based care.
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